Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings

Ashwini Shete1*, Sampada Dhayarkar1, Ashwini Dhamanage1,6, Smita Kulkarni1, Manisha Ghate1, Shashikala Sangle2, Uttam Medhe3, Vinita Verma4, Shobini Rajan4, Toshio Hattori5 and Raman Gangakhedkar1,7

Abstract

Background: Early detection of viremia in HIV infected patients on anti-retroviral therapy (ART) is important to prevent disease progression as well as accumulation of drug resistance mutations. This makes HIV viral load (VL) monitoring indispensable in HIV infected patients on ART. However VL, being an expensive test, results in heavy financial burden on health services. Hence, cheaper surrogate markers of viremia are desired to reduce overall cost of management of HIV infected patients.

Methods: We enrolled aviremic (n = 63, M:F = 31:32) and viremic (n = 43, M:F = 21:22) HIV infected patients at 1 year after ART initiation. Viremic individuals were identified as those having a plasma VL of more than 1000 copies/µl and aviremic individuals as less than 40 copies/µl. The study participants also included immuno-virologically discordant patients as they demonstrate differential degrees of immune-reconstitution and are likely to harbour concomitant infections influencing levels of immune-activation markers screened as the surrogate markers. Immune activation markers viz. plasma hs-CRP, soluble-CD14 and Galectin-9 levels were estimated by ELISA, IL-6 by luminex assay and percentages of CD38+ CD8+ cells were determined by flow cytometry. The levels were compared between viremic and aviremic patients and correlated with plasma viral load. Receiver operated curve (ROC) analysis was done for plasma Galectin-9 levels.

Results: Viremic patients had significantly higher levels of Galectin-9 and %CD38+ CD8+ cells (p values < 0.0001) than aviremic patients. Levels of the other activation markers did not differ between viremic and aviremic individuals. Galectin-9 levels (r = 0.76) and %CD38+ CD8+ cells (r = 0.39) correlated positively with VL. Area under curve for Galectin-9 levels for distinguishing between viremic and aviremic individuals was 0.98. Youden index, sensitivity, specificity, positive predictive value and negative predictive value for Galectin-9 levels were 0.87, 0.97, 0.90, 0.87 and 0.98, respectively, at the cut-off value of 5.79 ng/ml.

Conclusions: Plasma Galectin-9 levels could identify viremic individuals with sensitivity and specificity of more than 90%. Thus, they showed a potential to serve as a surrogate marker of viremia in HIV infected patients on ART and

*Correspondence: ashete@nariindia.org

1 ICMR-National AIDS Research Institute, 73-G Block, M.I.D.C, Bhosari, Pune, India

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Antiretroviral therapy (ART) has significantly impacted Human Immunodeficiency Virus (HIV) epidemic worldwide. The primary goal of ART is to suppress HIV viral load. UNAIDS 90-90-90 target for elimination of HIV as a public health threat includes achievement of viral suppression in the treated individuals as its last ‘90’ [1]. Failure to achieve viral suppression after ART initiation increases the risk of disease progression in them. Continued viral replication in presence of drug pressure has been shown to lead to development of drug resistant (DR) mutations. There is also a risk of development of multiple DR mutations if viremia persists for long time [2] further compromising options for second-line therapy. Hence early detection of viremia is a key to successful management of HIV infected patients on ART. Moreover, unsuppressed viremia increases the risk of secondary transmission of HIV which might lead to spread of drug resistant strains in the community. Hence, timely detection of failure of viral suppression is utmost important to achieve sustained control of HIV epidemic.

WHO has recommended annual viral load testing for monitoring HIV infected patients on ART [3]. However, viral load estimation is an expensive test requiring a sophisticated equipment, costly kits and skilled manpower. Hence, the patients are still monitored using clinical assessment or CD4 counts estimation in resource-poor countries [4]. Different point of care tests (POCTs) for viral load monitoring are also being evaluated to overcome the challenges posed by viral load testing. However robust POCTs offered at an affordable price are still not available [5]. Among 36.7 million estimated people living with HIV/AIDS globally, a vast majority reside in low- and middle-income countries [6]. Cost of viral load testing creates a heavy financial burden on these patients as well as on the national programs for HIV control run in such countries. This cost is incurred every year as there is no cure for HIV at present. Hence, cheaper surrogate biomarkers are desired to cut down this cost especially in low- and middle-income countries.

There have been several studies to identify surrogate biomarkers of viremia. CD4 count is being used as a marker of treatment success and is a part of patient management under our programme also. However, immune-virologically discordant responses are known to occur in 8–24% of the patients on ART [7] reducing sensitivity and specificity of the test in detecting viremic individuals. Hemoglobin and total lymphocyte count have been studied and shown to be reliable predictors of successful treatment outcome comparable to the increase in CD4 count [8]. CD38 expression has also been shown to correlate with viremia and has been proposed as a surrogate biomarker [9, 10]. Many of circulating immune activation markers have also been studied and shown to distinguish viral suppression from nonsuppression in HAART-treated patients [11].

We evaluated immune activation markers like high sensitivity C-reactive protein (hs-CRP), soluble CD14 (sCD14), bacterial lipopolysaccharide (LPS), Interleukin-6 (IL-6), Galectin-9, CD38 expressing CD8+ cells to determine their role as a possible surrogate marker of viremia. Being immune activation markers, their elevated levels have been reported in different infections even in HIV uninfected individuals. However, these markers were also shown to correlate with HIV viral loads in different studies and hence were selected in the present study [10, 12–16]. Among all these markers, only Galectin-9 has been shown to induce HIV reactivation in resting CD4 cells [12] indicating its role in contributing to viremia influencing viral load values. Although LPS has been shown to induce HIV reactivation through TLR4, it did not induce HIV reactivation in resting CD4 cells in one of the previous studies [17, 18]. Apart from HIV viremia driven activation, co-existing infections are also important drivers of immune activation [19]. Extent of immune-reconstitution is also likely to influence the levels of these markers as they are secreted by the cells of immune-system. Immuno-virologically discordant responders are more susceptible to infectious diseases than the treatment responders and they also represent individuals with differing degrees of viremia as well as immune-reconstitution. Hence we considered including the immuno-virologically discordant responders in addition to the concordant treatment responders and failure patients to evaluate the surrogate markers of viremia irrespective of the presence co-existing infections as well as the extent of immune-reconstitution.

Materials and methods

Characteristics of the study participants

This was a cross-sectional study conducted at ICMR-National AIDS Research Institute (ICMR-NARI). HIV infected patients at 1 year after initiation of anti-retroviral therapy were enrolled from Yashwantrao Chavan
Memorial Hospital (YCM) and B.J. Medical College (BJMC) ART centers. HIV infected patients visiting these centres were screened based on their CD4 counts at baseline and at 1 year as well as viral load values at 1 year to identify the eligible study participants. Patients with the rise of at least 100 CD4 cells/μl and viral load of less than 40 copies/ml were selected as treatment responders. Patients with the rise of less than 50 CD4 cells/μl and viral load of less than 40 copies/ml were selected as Immunologic non-responders (INR). Viremic patients with viral load of more than 1000 copies/ml were enrolled under two categories. Treatment failures had immunologic failure as defined under the national guidelines and Virologic non-responders (VNR) had an increase of at least 50 CD4 cells/μl. Blood samples collected after written informed consenting procedure. Plasma and PBMC were separated by density gradient centrifugation using Ficoll-Hypaque.

ELISA
Plasma concentrations of Galectin-9, hs-CRP, sCD14 were measured using commercially available ELISA Kits (R&D Systems, USA, and Biocheck Inc., USA). The ELISAs were performed according to manufacturers’ manuals. Concentrations of the immune-activation markers in the samples were determined by plotting standard curve as per the manufacturer’s instructions.

Endotoxin assay
Plasma LPS levels were determined using Limulus Amebocyte assay (GenScript Biotech Corp., USA). Plasma samples were heat-inactivated by incubating at 60 °C for 30 min before measuring the levels.

Flow cytometry
Frequency of CD38+ CD8+ cells in the study participants was determined in by flow cytometry using frozen PBMCs. PBMCs were revived and rested for 2 h before staining them with anti-CD3 PE/Dazzle 594 (Biolegend, USA), anti-CD8 APC/Cy7 and anti-CD38 FITC (both from BD Biosciences, USA) as described previously [20]. The cells were analysed on FACSAria Fusion using FACS-Diva software (BD Biosciences, USA).

Luminex assay
Interleukins 6 (IL-6) levels were estimated in plasma samples by a luminex assay along with other proinflammatory cytokines using Bio-Plex 200 system (Bio-Rad, USA) as per the manufacturer’s instructions.

Data analysis
Data analysis was done using GraphPad Prism software. Non-parametric tests were used for the statistical analysis. Mann–Whitney (one-tailed analysis) test was used for comparison between viremic and aviremic groups. Multiple group comparisons were assessed through Kruskal–Wallis test with Dunn’s multiple comparison testing. Correlations with viral loads and CD4 counts were done using Spearman correlation test. easyROC: a web-tool (ver. 1.3.1) was used for receiver operating characteristic (ROC) curve analysis.

Results
Characteristics of patients enrolled in the study are mentioned in Table 1. A total of 63 aviremic patients (Male:female 31:32) with age range of 23–62 years were enrolled in the study. Out of them 40 were responders and 23 were immunologic non-responders. Their enrolment median CD4 counts were 479 (range: 246–1387) cells/cmm and 227 (range: 13–360) cells/cmm, respectively. Viremic patients (n = 43; Male:female 21:22) were either treatment failure (n = 18) or virologic non-responders (n = 25). Their age ranged from 18 to 55 years. Their enrolment median CD4 counts were 89 (range: 19–331) cells/cmm and 317 (range: 99–809) cells/cmm, respectively. Their viral load varied from 1891 to 526,175 (median: 63,165) and 1056–889079 (median: 12,366) copies/ml, respectively.

Systemic immune activation was assessed by estimating CD38 expressing CD8+ cells and soluble markers like hs-CRP, sCD14, LPS, IL-6 and Galectin-9. Levels of these markers were compared between viremic versus aviremic individuals (Fig. 1). Levels of hs-CRP, sCD14,
LPS, IL-6 did not vary significantly between the viremic and aviremic individuals. However, plasma Galectin-9 levels and frequency of CD38 expressing CD8+ cells differed significantly among these two groups (p < 0.0001). The levels were further analysed among all concordant and discordant treatment response groups (Fig. 2). Only sCD14, Galectin-9 and percent CD38+ CD8+ cells showed significant differences by Kruskal–Wallis test.
(p values 0.0039, <0.0001, and <0.0001, respectively). VNR group had lower sCD14 levels than INR and failure patients when compared using Dunn’s post test. hs-CRP, LPS and IL-6 levels did not differ significantly among the study groups.

Patients from failures and VNRs groups had significantly higher levels of Galectin-9 in comparison with aviremic groups namely responders and INR groups as shown in Fig. 3a. However, frequency of CD38+CD8+ cells was significantly higher only in failure group as compared to aviremic patients from INR and responder groups as shown in Fig. 4a. Galectin-9 levels were also found to be significantly lower in patients showing immunologic response versus those not showing immunologic response (INR and failure patients) as shown in Fig. 3b. Galectin-9 levels correlated positively with plasma viral load values (r = 0.76, p < 0.0001) and negatively with CD4 cell counts (r = −0.472, p < 0.0001) in these patients (Fig. 3c, d). Similarly %CD38+CD8+ cells also correlated positively with plasma viral load values (r = 0.39, p = 0.0006) and negatively with CD4 cell counts (r = −0.316, p = 0.0051) as shown in Fig. 4b, c.

Since plasma Galectin-9 values correlated strongly with viral load values, ROC analysis was done to determine discriminatory potential of Galectin-9 (Fig. 5). Area under ROC curve (AUC) for Galectin-9 levels was 0.98. Cut off of 5.79 ng/ml was identified to differentiate patients with viremia from those without viremia with sensitivity and specificity of 0.97 and 0.90, respectively.

**Discussion**

We screened systemic immune activation markers in HIV infected patients showing immuno-virologic concordant and discordant responses to anti-retroviral therapy for their possible role in identifying HIV infected patients with viremia. Immune activation markers are likely to be influenced by immune status of the patients and may vary depending on the extent of immunosuppression in these patients. Additionally, presence of other co-existing...
infections may influence their levels. Hence we considered including immune-virologically discordant patients for representing viremic and aviremic individuals with differing degrees of immunosuppression. Moreover, we had also shown that patients with immunologic non-response were likely to have frequent co-existing infections [20] possibly impacting levels of immune activation markers.
Among the systemic immune activation markers studied, only plasma Galectin-9 levels and frequency of CD38 expressing CD8 cells differed significantly between viremic and aviremic patients. These markers were significantly high in viremic groups as compared to the groups with aviremia. Plasma Galectin-9 levels and %CD38+CD8+ also correlated positively with viral loads in these patients indicating association of these markers with viral replication. CD38 expression has also been shown correlate with viremia and had been proposed as a surrogate biomarker of viremia [9, 10]. Positive correlation between Galectin-9 levels and plasma HIV viral load was detected in a couple of studies [12, 21]. Galectin-9 has been shown to potently reactivate latent HIV in CD4 cells ex vivo [12]. Enhanced HIV transcription by Galectin-9 has been shown through T cell receptor (TCR) based ERK signalling [22]. Since viremic patients in our study were virologically failing patients on ART, we did not have viral load values at a very high end of the viral load scale. A larger study with more number of patients having a high level viremia needs to be conducted to confirm the findings. We also found inverse correlation of Galectin-9 levels with CD4 cells counts as reported previously [23] indicating a role of Galectin-9 in HIV disease progression.

Galectin-9 levels were further used for ROC analysis for determining their predictive value in identifying viremic individuals. AUC value of 0.98 indicated high accuracy of these levels in identifying viremic patients. The analysis showed more than 90% sensitivity and specificity in identifying viremic patients at the cut off levels of 5.79 ng/ml. Positive predictive value (87%) for the levels was slightly lower than the negative predictive value (98%). Very high sensitivity and negative predictive value indicated role of the levels as a screening test for identifying viremic patients. However considering its lower positive predictive value and specificity, the results would be required to be confirmed further by viral load test to avoid misidentifying aviremic individuals as those having virologic failure. The rate of virologic failure has been shown to vary from 2.9 to 26.0% in patients in Sub-Saharan Africa and Southeast Asia [24] indicating viral suppression in more than 70% individuals who might not require viral load testing if a screening test is used having a huge financial implication. Lower specificity of these levels is likely because they tend to increase in other infectious diseases also [25–30]. INR patients, who showed higher frequency of infectious diseases in our study [20], had significantly lower Galectin-9 levels than both the viremic groups. Patients from VNR and failure groups are also more likely to suffer from opportunistic infections [31] which might influence Galectin-9 levels. However HIV viral load values have also been shown to increase in presence of coinfections [29] and hence, viral load testing is not recommended within 4 weeks of any diagnosed infection [32].

Other markers like hs-CRP, sCD14, LPS and IL-6 did not vary significantly among viremic and aviremic individuals. Virally suppressive ART had been shown to have no effect on CRP levels in one of the studies [33] and could be a possible reason for similar levels detected in viremic and aviremic individuals in our study. Similarly, no difference in sCD14 and LPS levels has been reported in virally suppressed versus those who are not suppressed [34]. However, the same study reported positive association of IL-6 with HIV viral RNA copies [34]. In contrast, one of the studies had shown that although pre-treatment plasma IL-6 levels correlated weakly with HIV-1 viral load, they failed to decrease proportionately with the viral load after ART [35]. Such conflicting results might be possibly because of multiple factors like the extent of immune reconstitution, presence of co-existing conditions influencing levels of inflammatory markers. Interestingly, sCD14 levels were significantly lower in VNR group than Failure as well as INR groups. Higher sCD14 levels were shown to be associated with immunologic failure [36]. Since VNR patients did not fail immunologically they might not have had higher sCD14 values.

**Conclusion**

Thus systemic immune activation markers like hs-CRP, sCD14, IL-6, LPS did not vary significantly in viremic and aviremic individuals precluding their role as surrogate markers of viremia in HIV infected patients on ART. Among the two markers, plasma Galectin-9 levels and frequency of CD38CD8+ cells which differed significantly in these individuals, plasma Galectin-9 levels correlated strongly with viral load values. ROC curve analysis demonstrated very high sensitivity and slightly lower specificity of the levels in diagnosing the patients with viremia suggesting its role as a screening test for identifying viremic HIV infected patients on ART. This cheaper and simpler ELISA test could help to cut down cost of HIV management tremendously and also might help to increase coverage of virologic monitoring even in resource-limited settings and hard to reach population. However, the findings need to be confirmed on a larger sample size and in HIV infected patients with varying durations of ART since the patients included in the study were on ART for 1 year.

**Abbreviations**

HIV: Human immunodeficiency virus; ART: Anti-retroviral therapy; VL: HIV viral load; INR: Immunologic non-responders; VNR: Virologic non-responders; hs-CRP: High sensitivity C-reactive protein; sCD14: Soluble CD14; LPS: Bacterial lipopolysaccharide; IL-6: Interleukin-6; ROC: Receiver operating characteristic curve; AUC: Area under ROC curve.
Acknowledgements

We thank staff from immunology laboratory, virology laboratory and ART centers for their help during the study. We especially thank the study participant for their time and participation in this study. We thank investigators and participants of Viral Suppression Study from where few of the VNR samples were taken.

Authors’ contributions

AS, SD, RG, TH conceived and designed the study. AD performed Data acquisition and analysis. SK performed viral load testing and data analysis. MG, SS, UM identified eligible participants and performed data analysis. AS performed the data analysis, interpretation of data and drafted the manuscript. SR and VV supervised data collection. All authors read and approved the final manuscript.

Funding

This work was supported by National AIDS Control Organisation, India [Grant Number: T-11020/39/2013-NACO (R&D)].

Availability of data and materials

Data supporting the findings are available in the results, in the tables and figures of the manuscript.

Ethics approval and consent to participate

The study was approved by Ethics committees of ICMR-National AIDS Research Institute and National AIDS Control Organization (Protocol Number: NARI-EC/2014-07). Written informed consent was obtained from all the participants before enrolling them in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 ICMR-National AIDS Research Institute, 73-G Block, M.I.D.C., Bhosari, Pune, India. 2 B.J. Medical College and Sassoon General Hospital, Jai Prakash Narayan Road, Near Pune Railway Station, Pune, India. 3 Yashwantrao Chavan Memorial Hospital, Sant Tukaram Nagar, Pimpri, Pune, India. 4 National AIDS Control Organization, Chandrolak Building, 36, Janpath, New Delhi, India. 5 Kibi International University, Takahashi, Okayama, Japan. 6 Present Address: National Centre for Cell Sciences, University of Pune Campus, University Road, Ganeshkhand, Pune, India. 7 Present Address: Indian Council of Medical Research, V. Ramalingaswami Bhavan, Ansari Nagar, P.O. Box No. 4911, New Delhi, India.

Received: 31 December 2019 Accepted: 7 July 2020

Published online: 16 July 2020

References

1. UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. 2014. http://www.unaids.org/en/resources/909090. Geneva. Accessed 09 Sept 2019.
2. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwickard G, Chaisson RE, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49(12):1928–35.
3. WHO and Switzerland. What’s new in treatment monitoring: viral load and CD4 testing. HIV treatment and care. 2017. https://apps.who.int/iris/bitstream/handle/10665/235388/WHO-HIV-2017.22-eng.pdf?sequence=9c32a80ca4668b37fe21a7acc9cfe06a1f7e1e1e1.
4. Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, et al. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis. 2017;17(11):e26–9.
5. Brook G. HIV viral load point-of-care testing: the what, the why, and the wherefore. Sex Transm Infect. 2018;94(6):394–5.
6. HIV.gov. HIV BASICS—overview: data & trends: global statistics. 2018. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics. Accessed 18 July 2019.
7. Casotti JA, Passos LN, Oliveira FJ, Cerutti C JR. Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil. Rev Inst Med Trop Sao Paulo. 2011;53(6):301–7.
8. Florence E, Dreeszen C, Schrooten W, Van Esbroeck M, Kestens L, Fransen K, et al. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiretroviral treatment. Int J STD AIDS. 2004;15(8):538–42.
9. Njuguna ANJOWR, Mpoke S, Mwiri M, Mathurna L, Mathaua R, Otiene P, Nyakundi P. CD38 as surrogate marker for HIV infection in antiretroviral naive and antiretroviral experienced patients in Kenya. Adv Mol Diag. 2016;1:107.
10. Rosso R, Fenoglio D, Terranova MP, Lantieri F, Risso D, Pontali E, et al. Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths. Scand J Immunol. 2010;71(1):45–51.
11. Malherbe G, Steel HC, Cassol S, de Oliveira T, Seebregts CJ, Anderson R, et al. Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection. Mediat Inflamm. 2014;2014:198413.
12. Abdel-Mohsen M, Chavez L, Zandon R, Chew GM, Deng X, Daniel A, et al. Human Galectin-9 is a potent mediator of HIV transcription and reactivation. PloS Pathog. 2016;12(6):e1005677.
13. Baroncelli S, Galluzzo CM, Pirillo MF, Mancini MG, Weimer LE, Andreotti M, et al. Microbial translocation is associated with residual viral replication in HIV-treated patients with <50 copies/ml HIV-1 RNA. J Clin Virol. 2009;46(4):367–70.
14. Lau B, Sharratt AR, Kingsley LA, Post W, Paella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166(1):64–70.
15. Lien E, Aukrust P, Sundan A, Muller F, Floiland SS, Espesk T. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 1998;92(18):2084–92.
16. Rollenhagen C, Asin SN. Enhanced HIV-1 replication in ex vivo eccentocervical tissues from post-menopausal women correlates with increased inflammatory responses. Mucosal Immunol. 2011;4(6):671–81.
17. Equils O, Faure E, Thomas L, Buluy T, Trushin S, Ardit M. Bacterial lipo polysaccharide activates HIV long terminal repeat through Toll-like receptor 4. J Immunol. 2001;166(4):2342–37.
18. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, et al. Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology. 2013;10:119.
19. Boulougoura A, Sereti I. HIV infection and immune activation: the role of confictions. Curr Opin HIV AIDS. 2016;11(2):191–200.
20. Shete A, Dhayarkar S, Sangale S, Medhe U, Panchal N, Rahane G, et al. Incomplete functional T-cell reconstitution in immunological non-responders at one year after initiation of antiretroviral therapy possibly predisposes them to infectious diseases. Int J Infect Dis. 2019;81:114–22.
21. Tandon R, Chew GM, Byron MM, Borrow P, Niki T, Hirashima M, et al. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retroviruses. 2014;30(7):654–64.
22. Colomb F, Giron LB, Premeaux TA, Mitchell BJ, Niki T, Papasavvas E, et al. Galectin-9 mediates HIV transcription by inducing TCR-dependent ERK signaling. Front Immunol. 2019;10:267.
23. Jost S, Moreno-Nieves UT, Garcia-Beltran WF, Randis K, Reardon J, Toth I, et al. Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology. 2013;10:74.
24. Aghokeng AF, Monlea M, Fymard-Duvensay S, Dagnana A, Kania D, Ngo-Giang-Huong N, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis. 2014;58(1):99–109.
25. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3/Galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–51.
26. Liu KT, Liu YH, Chen YH, Lin CY, Huang CH, Yen MC, et al. Serum Galectin-9 and Galectin-3-binding protein in acute dengue virus infection. Int J Mol Sci. 2016;17(6):832.

27. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, et al. A crucial role for Kupffer cell-derived Galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS ONE. 2010;5(3):e9504.

28. Reddy PB, Sehrawat S, Suryawanshi A, Rajasagi NK, Mulik S, Hirashima M, et al. Influence of Galectin-9/Tim-3 interaction on herpes simplex virus-1 latency. J Immunol. 2011;187(11):5745–55.

29. Sharma S, Sundararajan A, Suryawanshi A, Kumar N, Veiga-Parga T, Kuchroo VK, et al. T cell immunoglobulin and mucin protein 3 (Tim-3)/ Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci USA. 2011;108(47):19001–6.

30. Shiratori B, Zhao J, Okumura M, Chagan-Yasutan H, Yanai H, Mizuno K, et al. Immunological roles of elevated plasma levels of matricellular proteins in Japanese patients with pulmonary tuberculosis. Int J Mol Sci. 2016;18(1):19.

31. Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol. 2005;76(2):153–60.

32. NACO MoHaFW, Government of India. National technical guidelines on anti retroviral treatment. http://www.nacogov.in/sites/default/files/NACO%20-%20National%20Technical%20Guidelines%20on%20ART_October%202019%20%281%29pdf. 2018.

33. Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011;27(5):461–8.

34. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.

35. Shive CL, Biancotto A, Funderburg NT, Plich-Cooper HA, Valdez H, Margolis L, et al. HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr. 2012;61(2):145–52.

36. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217–26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.